Abraxane
Showing 1 - 25 of 531
Immunotherapy;Envafolimab; Esophageal Cancer Trial (Envafolimab, Abraxane, Cisplatin)
Not yet recruiting
- Immunotherapy;Envafolimab; Esophageal Cancer
- Envafolimab
- +2 more
- (no location specified)
Apr 24, 2023
Pancreatic Tumors Trial in Shanghai (Sofantinib?abraxane?gemcitabine, Abraxane combined with gemcitabine)
Not yet recruiting
- Pancreatic Neoplasms
- Sofantinib、abraxane、gemcitabine
- Abraxane combined with gemcitabine
-
Shanghai, ChinaFudan University ShangHai Cancer Center
Jul 31, 2023
Breast Cancer Trial in Nanjing (Pyrotinib, trastuzumab, abraxane)
Not yet recruiting
- Breast Cancer
- Pyrotinib, trastuzumab, abraxane
-
Nanjing, Jiangsu, ChinaJiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Dec 20, 2022
Metastatic Adenocarcinoma of the Pancreas Trial in Soeul (Minnelide)
Recruiting
- Metastatic Adenocarcinoma of the Pancreas
- Minnelide
-
Soeul, Korea, Republic ofSamsung Medical Center
Dec 8, 2022
Advanced Breast Cancer Trial (SYHX2011 and Abraxane®)
Not yet recruiting
- Advanced Breast Cancer
- SYHX2011 and Abraxane®
- (no location specified)
Mar 2, 2022
Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker
Suspended
- Recurrent Aggressive Non-Hodgkin Lymphoma
- +5 more
- Laboratory Biomarker Analysis
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 12, 2023
Melanoma Trial in Houston (ABI-007, Ipilimumab, Phone Call)
Completed
- Melanoma
- ABI-007
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jan 12, 2022
Advanced Adenocarcinoma, Metastatic Adenocarcinoma Trial in Philadelphia (Hydroxychloroquine (HCQ), Gemcitabine, Abraxane)
Completed
- Advanced Adenocarcinoma
- Metastatic Adenocarcinoma
- Hydroxychloroquine (HCQ)
- +2 more
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Mar 29, 2022
Urothelial Carcinoma Trial in Ann Arbor (Pembrolizumab, Abraxane)
Active, not recruiting
- Urothelial Carcinoma
- Pembrolizumab
- Abraxane
-
Ann Arbor, MichiganUniversity of Michigan Comprehensive Cancer Center
Dec 15, 2021
Metastatic Breast Cancer Trial in New York (PU-H71, Nab-paclitaxel)
Completed
- Metastatic Breast Cancer
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Dec 17, 2021
Cord Compression Trial in Saint Louis (Radiation therapy, nab-Paclitaxel)
Terminated
- Cord Compression
- Radiation therapy
- nab-Paclitaxel
-
Saint Louis, MissouriWashington University School of Medicine
Oct 15, 2021
Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Unresectable Breast Carcinoma Trial in Aurora (Nab-paclitaxel,
Withdrawn
- Triple Negative Breast Cancer
- +4 more
- Nab-paclitaxel
- +3 more
-
Aurora, ColoradoUniversity of Colorado Hospital
Dec 2, 2022
Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V Trial in Beijing (KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)
Recruiting
- Solid Tumor, Adult
- +4 more
- KRAS-EphA-2-CAR-DC
- +3 more
-
Beijing, Beijing, ChinaBiotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022
Patients With Stage IV or Recurrent Adenocarcinoma of the Lung Trial (Abraxane, Gemcitabine)
Completed
- Patients With Stage IV or Recurrent Adenocarcinoma of the Lung
- Abraxane
- Gemcitabine
- (no location specified)
Sep 28, 2021
Solid Tumor, Adult, Lymphoma, EphA2 Overexpression Trial in Beijing (TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)
Recruiting
- Solid Tumor, Adult
- +6 more
- TP53-EphA-2-CAR-DC
- +3 more
-
Beijing, Beijing, ChinaBiotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022
Gastric Cancer in Situ, Pancreatic Cancers, Biliary Cancers Trial in Taipei (Oxaliplatin, Albumin-Bound Paclitaxel
Completed
- Gastric Cancer in Situ
- +2 more
- Oxaliplatin
- +3 more
-
Taipei, TaiwanTaiwan Cooperative Oncology Group, National Health Research Inst
Apr 5, 2022
HR+/HER2- Breast Cancer Trial (Tucidinostat, nab-paclitaxel)
Not yet recruiting
- HR+/HER2- Breast Cancer
- (no location specified)
Nov 21, 2022
Breast Cancer Trial in Boston (Pembrolizumab, Nab-Paclitaxel, Biopsy)
Active, not recruiting
- Breast Cancer
- Pembrolizumab
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Aug 22, 2022
Ovarian Cancer Trial in Maywood (Decitabine, Carboplatin, Paclitaxel)
Not yet recruiting
- Ovarian Cancer
- Decitabine
- +3 more
-
Maywood, IllinoisLoyola University Medical Center
Aug 1, 2023
Objective Response Rate Trial in Jinan (albumin-bound paclitaxe combined with bevacizumab biosimilar)
Recruiting
- Objective Response Rate
- albumin-bound paclitaxe combined with bevacizumab biosimilar
-
Jinan, Shandong, ChinaQilu Hospital of Shandong University
Oct 7, 2021
Breast Cancer Trial in Houston (Panitumumab, Nab-paclitaxel, Carboplatin)
Completed
- Breast Cancer
- Panitumumab
- +5 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 20, 2022
Pancreas Cancer, Non-Resectable Pancreas Carcinoma Trial in Aalborg (Gemcitabine, Nab paclitaxel)
Not yet recruiting
- Pancreas Cancer
- Non-Resectable Pancreas Carcinoma
- Gemcitabine
- Nab paclitaxel
-
Aalborg, DenmarkDepartment of Oncology, Aalborg University Hospital
May 1, 2023